The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared with a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

American Journal of Gastroenterology

Volumn 111, Issue 7, 2016, Pages 949-956

  Suzuki, Sho ^a,b   Gotoda, Takuji ^a   Kusano, Chika ^a,b   Iwatsuka, Kunio ^a   Moriyama, Mitsuhiko ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yuri Kumiai General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIALLERGIC AGENT; CLARITHROMYCIN; LANSOPRAZOLE; RABEPRAZOLE; STEROID; UREA C 13; VONOPRAZAN; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; SULFONAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROPENSITY SCORE; RASH; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UREA BREATH TEST; BREATH ANALYSIS; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG MONITORING; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PROCEDURES;

AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LANSOPRAZOLE; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; PYRROLES; RABEPRAZOLE; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84976548292     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.182     Document Type: Article

References (41)

1. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
2. Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121-8.
3. Chey WD, Wong BC. Practice Parameters Committee of the American College of G. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
4. Lee JW, Kim N, Kim JM et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013; 18: 206-14.
5. Shin JM, Sachs G. Long lasting inhibitors of the gastric H, K-ATPase. Expert Rev Clin Pharmacol 2009; 2: 461-8.
6. Hori Y, Imanishi A, Matsukawa J et al. 1-[5-(2-Fluorophenyl)-1-(pyridin- 3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
7. Ross ME, Kreider AR, Huang YS et al. Propensity score methods for analyzing observational data like randomized experiments: challenges and solutions for rare outcomes and exposures. Am J Epidemiol 2015; 181: 989-95.
8. Fujioka T, Aoyama N, Sakai K et al. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol 2012; 47: 276-83.
9. Lee JY, Kim N, Kim MS et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 2014; 59: 1235-43.
10. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414-25.
11. Tang HL, Li Y, Hu YF et al. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013; 8: e62162.
12. Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol 2009; 2: 295-314
13. Matsukawa J, Hori Y, Nishida H et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol 2011; 81: 1145-51.
14. Hori Y, Matsukawa J, Takeuchi T et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011; 337: 797-804
15. Jenkins H, Sakurai Y, Nishimura A et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
16. Murakami K, Sakurai Y, Shiino M et al. Vonoprazan, a novel potassiumcompetitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut; e-pub ahead of print 2 March 2016.
17. Sakurai Y, Mori Y, Okamoto H et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study. Aliment Pharmacol Ther 2015; 42: 719-30.
18. Ashida K, Sakurai Y, Hori T et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016; 43: 240-51.
19. Desta Z, Zhao X, Shin JG et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58.
20. Strom CM, Goos D, Crossley B et al. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med 2012; 14: 95-100.
21. Grayson ML, Eliopoulos GM, Ferraro MJ et al. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-9.
22. Scott D, Weeks D, Melchers K et al. The life and death of Helicobacter pylori. Gut 1998; 43 ( Suppl 1 ): S56-60.
23. Park CS, Lee SM, Park CH et al. Pretreatment antimicrobial susceptibilityguided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol 2014; 109: 1595-602.
24. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6: 183-98.
25. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection - the maastricht IV/ florence consensus report. Gut 2012; 61: 646-64.
26. Calvet X, Garcia N, Lopez T et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-9.
27. Zullo A, De Francesco V, Hassan C et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-7.
28. Chung JW, Jung YK, Kim YJ et al. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012; 27: 1675-80.
29. Kim BG, Lee DH, Ye BD et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007; 12: 31-5.
30. Zhou L, Zhang J, Chen M et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol 2014; 109: 535-41.
31. Fuccio L, Minardi ME, Zagari RM et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-62.
32. Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol 2015; 30: 1338-45.
33. Lee HJ, Kim JI, Lee JS et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015; 21: 351-9.
34. Oh DH, Lee DH, Kang KK et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol 2014; 29: 1171-6.
35. Zullo A, Scaccianoce G, De Francesco V et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647-50.
36. Nishida T, Tsujii M, Tanimura H et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. World J Gastroenterol 2014; 20: 4362-9.
37. Wong BC, Wong WM, Yee YK et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 1959-65.
38. Ebo DG, Leysen J, Mayorga C et al. The in vitro diagnosis of drug allergy: status and perspectives. Allergy 2011; 66: 1275-86.
39. Kamiya K, Nishio E, Horio A et al. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. J Dermatol 2015; 43: 340-1.
40. Riemer AB, Gruber S, Pali-Scholl I et al. Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model. Clin Exp Allergy 2010; 40: 486-93.
41. Brunner R, Wallmann J, Szalai K et al. Aluminium per se and in the anti-acid drug sucralfate promotes sensitization via the oral route. Allergy 2009; 64: 890-7.